Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study.
Abhyuday KumarNeeraj KumarArunima PattanayakAjeet KumarSaravanan PalavesamPradhan Manigowdanahundi NagarajuRekha Das
Published in: Acute and critical care (2024)
The CI with itolizumab is similar to tocilizumab. Better oxygenation can be achieved with itolizumab and it can be a substitute for tocilizumab in managing severe COVID-19.